MolDX: EndoPredict® Breast Cancer Gene Expression Test

This contractor provides limited coverage for the EndoPredict® test only for post-menopausal women with early-stage (T1-T3, N0-N1) ER-positive, HER2-negative breast cancer who are node-negative or have 1–3 positive nodes and for whom adjuvant endocrine therapy is being considered. The test is intended to identify patients at sufficiently low 10-year distant recurrence risk who may safely forgo chemotherapy; coverage does not extend to patients outside this specified population.

"Coverage for the EndoPredict® breast cancer gene expression test is provided for post-menopausal women with early-stage invasive breast cancer (TNM stage T1-T3, N0-N1) that is estrogen receptor (ER..."

Sign up to see full coverage criteria, indications, and limitations.